Table S1 Baseline characteristics and treatment profile of patients after propensity score matching

Characteristics	Outcome: rwPFS				Outcome: OS			
	Cohort A (N=76)	Cohort B (N=76)	Cohort C (N=76)	P value	Cohort A (N=68)	Cohort B (N=68)	Cohort C (N=68)	P value
Gender				0.08				0.07
Male	61 (80.3)	63 (82.9)	52 (68.4)		54 (79.4)	58 (85.3)	47 (69.1)	
Age group				0.35				0.77
<65 years	47 (61.8)	39 (51.3)	47 (61.8)		40 (58.8)	37 (54.4)	41 (60.3)	
Smoking				0.15				0.37
Former/current	43 (56.6)	52 (68.4)	41 (53.9)		39 (57.4)	46 (67.6)	39 (57.4)	
Never	33 (43.4)	24 (31.6)	35 (46.1)		29 (42.6)	22 (32.4)	29 (42.6)	
ECOG PS				0.78				0.08
0/1	64 (84.2)	65 (85.5)	67 (88.2)		54 (79.4)	59 (86.8)	63 (92.6)	
2	12 (15.8)	11 (14.5)	9 (11.8)		14 (20.6)	9 (13.2)	5 (7.4)	
Metastasis								
Brain metastasis	32 (42.1)	31 (40.8)	27 (35.5)	0.68	29 (42.6)	28 (41.2)	27 (39.7)	0.94
Liver metastasis	28 (36.8)	25 (32.9)	19 (25)	0.28	22 (32.4)	24 (35.3)	19 (27.9)	0.65
Bone metastasis	25 (32.9)	24 (31.6)	21 (27.6)	0.77	32 (47.1)	24 (35.3)	21 (30.9)	0.13

Categorical variables are presented as n (%). rwPFS, real-world progression-free survival; OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group Performance Status.